Search

Displaying results 6551 - 6560 of 10000 in total
  1. Drug

    Onalespib

    go.drugbank.com/drugs/DB06306
    Investigational

  2. Drug

    Avasimibe

    go.drugbank.com/drugs/DB06442
    Experimental

  3. Drug

    Levovirin

    go.drugbank.com/drugs/DB06523
    Experimental

  4. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  5. Drug

    Anamorelin

    go.drugbank.com/drugs/DB06645
    Investigational

  6. Drug

    Cefmetazole

    go.drugbank.com/drugs/DB00274
    Approved

    It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

  7. Drug

    Becaplermin

    go.drugbank.com/drugs/DB00102
    ApprovedInvestigational

    Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds. … Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae.

  8. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  9. Drug

    Levcromakalim

    go.drugbank.com/drugs/DB21154
    Investigational

    Levcromakalim is under investigation in clinical trial NCT04853797 (Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)). … Levcromakalim is a small molecule drug. The usage of the INN stem '-kalim' in the name indicates that Levcromakalim is a potassium channel activator, antihypertensive.

  10. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm.